Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 2, 2012, Pages 313-322

  Lee, Myoung Ha ^a,b   Kim, Seung Up ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b,c   Choi, Eun Hee ^a,b   Lee, Kwang Hun ^a,b   Lee, Do Yun ^a,b   Seong, Jinsil ^a,b,c   Han, Kwang Hyub ^a,b,c   Chon, Chae Yoon ^a,b   Park, Jun Yong ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Alpha fetoprotein; Concurrent chemoradiation therapy; Des gamma carboxy prothrombin; Hepatic artery hepatocellular carcinoma; Infusional chemotherapy

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DECARBOXYPROTHROMBIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; FEMALE; HEPATIC ARTERY; HUMAN; IMPLANTABLE PORT SYSTEM; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84862924426     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06867.x     Document Type: Article

References (34)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 1999; 83: 18-29.
2. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J. Gastroenterol. 2005; 11: 7391-400.
3. Kim SU, Kim do Y, Park JY etal. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J. Cancer Res. Clin. Oncol. 2008; 134: 1377-84.
4. Park JY, Ahn SH, Yoon YJ etal. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-37.
5. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-95.
6. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
7. Ben-Josef E, Normolle D, Ensminger WD etal. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 2005; 23: 8739-47.
8. Sangro B, Bilbao JI, Inarrairaegui M, Rodriguez M, Garrastachu P, Martinez-Cuesta A. Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres. Dig. Dis. 2009; 27: 164-9.
9. Riaz A, Ryu RK, Kulik LM etal. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J. Clin. Oncol. 2009; 27: 5734-42.
10. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205-16.
11. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35: 421-30.
12. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14: 717-25.
13. Chan SL, Mo FK, Johnson PJ etal. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 2009; 27: 446-52.
14. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl. 1): 57-63.
15. Kim do Y, Paik YH, Ahn SH etal. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007; 72 (Suppl. 1): 52-7.
16. Yamamoto K, Imamura H, Matsuyama Y etal. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann. Surg. Oncol. 2009; 16: 2795-804.
17. Kim HS, Park JW, Jang JS etal. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J. Clin. Gastroenterol. 2009; 43: 482-8.
18. Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J. Hepatol. 2004; 10: 88-98.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
20. Aoyagi Y, Oguro M, Yanagi M etal. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77:1781-6.
21. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-8.
22. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig. Dis Sci. 1991; 36: 1787-92.
23. Toyoda H, Kumada T, Kaneoka Y etal. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J. Hepatol. 2008; 49: 223-32.
24. Ho S, Johnson PJ, Leung WT, Lau WY. Combating hepatocellular carcinoma with an integrated approach. Chin. Med. J. (Engl.) 1999; 112: 80-3.
25. Lau WY, Ho S, Leung WT, Chan M, Lee WY, Johnson PJ. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? Hepatogastroenterology 2001; 48: 338-40.
26. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
27. Seong J, Park HC, Han KH etal. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 1331-5.
28. Balm AJ, Rasch CR, Schornagel JH etal. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 2004; 26: 485-93.
29. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J. Gastroenterol. 2007; 42: 962-8.
30. Lee JS, Heo J, Libbrecht L etal. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 2006; 12: 410-6.
31. Higashi T, Hatano E, Ikai I etal. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37: 468-82.
32. Dierckx R, Maes A, Peeters M, Van De Wiele C. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q. J. Nucl. Med. Mol. Imaging. 2009; 53: 336-42.
33. Bloomer JR, Waldmann TA, McIntire R, Klatskin G. Relationship of serum alpha-fetoprotein to the severity and duration of illness in patients with viral hepatitis. Gastroenterology 1975; 68: 342-50.
34. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. Alpha-fetoprotein in noneoplastic hepatic disorders. JAMA 1975; 233: 38-41.